Australia markets closed

Cynata Therapeutics Limited (CYP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2950+0.0050 (+1.72%)
At close: 04:10PM AEST
Full screen
Previous close0.2900
Open0.2900
Bid0.2850 x 1582700
Ask0.2950 x 3535900
Day's range0.2900 - 0.3050
52-week range0.1050 - 0.3050
Volume145,508
Avg. volume136,500
Market cap52.991M
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings date23 July 2024 - 28 July 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Further CYP-001 GvHD Clinical Data Published in Nature Medicine

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.

  • PR Newswire

    Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

  • PR Newswire

    First Patient Treated in Phase 2 GvHD Trial

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).